Stead added that while SLT is now the first treatment that is offered to patients, a range of topical medications in the form of eyedrops still play an important role in glaucoma management. Turning ...

Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, announces the first patient in the international SAPPHIRE Trial has been treated with Avisi's ...

Researchers have found in largest prospective dataset on tube shunt outcomes that Chronic hypotony is a rare complication of tube shunt surgery that often leads to reduced visual acuity and the key ...

The John A. Moran Eye Center is pleased to welcome Roya Garakani, DO, who specializes in glaucoma, cataracts, and complex surgeries involving the front part of the eye. Garakani earned her Doctor of ...

SEOUL, South Korea, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Seoul National University Hospital (SNUH) is set to lead Korea’s participation at MEDICA 2025, the world’s largest medical trade fair, taking ...

The company's portfolio includes state-of-the-art treatments for glaucoma and other ocular conditions. These include its flagship VisiPlate ® aqueous shunt, V-001 sustained intraocular drug-delivery ...

REDWOOD CITY, Calif., Nov. 3, 2025 /PRNewswire/ -- Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, presented positive twelve-month clinical ...

Christine Funke, MD, a glaucoma specialist at Barnet Dulaney Perkins Eye Center in Phoenix, Arizona, discussed how minimally invasive glaucoma surgery (MIGS) has been able to offer her patients better ...

The multi‐site VITA trial, a prospective pilot study designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate® device, enrolled and treated 15 subjects (mean ...